Crystalline and amorphous famotidine malate as pathways to prevent polymorphic transformation with improved dissolution.
Co-amorphous system
Crystal engineering
Famotidine
Physicochemical characterization
Solubility assays
Journal
International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127
Informations de publication
Date de publication:
25 Jul 2023
25 Jul 2023
Historique:
received:
12
10
2022
revised:
09
05
2023
accepted:
11
05
2023
medline:
24
7
2023
pubmed:
18
5
2023
entrez:
17
5
2023
Statut:
ppublish
Résumé
Famotidine (FMT) is an orally administered histamine H2-receptor blocker with limited bioavailability since it exhibits low solubility and low permeability. In addition, the recent withdrawal of ranitidine from the market, makes famotidine an interesting candidate to obtain solid forms with improved pharmacokinetic performance. In this work, crystal engineering concepts and the co-amorphous formation strategy were applied to obtain two novel solids. Crystalline famotidine malate (FMT-MT) and a vitreous phase (FMT-MTa) were prepared by solvent evaporation and mechanochemical synthesis, respectively. FMT-MT (monoclinic, S.G. P2
Identifiants
pubmed: 37196883
pii: S0378-5173(23)00473-8
doi: 10.1016/j.ijpharm.2023.123053
pii:
doi:
Substances chimiques
Famotidine
5QZO15J2Z8
malic acid
817L1N4CKP
Malates
0
Histamine H2 Antagonists
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
123053Informations de copyright
Copyright © 2023 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.